eligibility_summary
Eligible: ECOG 0–1, tissue available, solid tumors per cohort (urothelial, TNBC, NSCLC, ovarian/fallopian tube, cervical, HNSCC, prostate, others in A1). Prior therapy: A1/C1–5 no standard options, A2/B1/B2 ≥1 prior. Enfortumab vedotin: A1/A2/C1–5 allowed, B1 naive, B2 required. Disease: A1 measurable or not, others measurable. Exclude: uncontrolled CNS mets/hypercalcemia/diabetes/infection, corneal dz, unresolved tox, CV dz, recent obstruction/VTE/bleeding, QTcF ≥470, ILD/pneumonitis, prior ≥G3 EV skin tox, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06238479 is a Phase 1a/1b, open-label study of LY4101174, an intravenous antibody-drug conjugate (ADC) targeting Nectin-4 (PVRL4). Mechanism: the anti–Nectin-4 monoclonal antibody binds Nectin-4 on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills Nectin-4–expressing cells, activity depends on antigen expression and ADC uptake, with potential bystander effect. Targets: Nectin-4–positive tumor cells, Nectin-4 is a tumor-associated cell-adhesion molecule in the nectin/afadin adherens junction pathway. Tumor types include urothelial carcinoma, triple-negative breast cancer, NSCLC, ovarian, cervical, head and neck SCC, pancreatic, esophageal, and prostate cancers. The trial includes dose escalation/optimization and expansion (including EV-naive and EV-pretreated UC) to define RP2D and assess efficacy/safety.